Drug Overview
Dulera ([mometasone + formoterol]; Merck & Co) is an oral inhalation drug that contains a combination of mometasone (an inhaled corticosteroid) and formoterol (a long-acting beta 2 agonist). Mometasone is a glucocorticoid receptor agonist with potent anti-inflammatory activity. Formoterol fumarate is a beta-2 adrenergic receptor agonist and acts as a bronchodilator. Dulera is approved in the US where it is indicated for the treatment of asthma in adults and adolescents aged 12 years and above.
Dulera ([mometasone + formoterol]; Merck & Co) is an oral inhalation drug that contains a combination of mometasone (an inhaled corticosteroid) and formoterol (a long-acting beta 2 agonist). Mometasone is a glucocorticoid receptor agonist with potent anti-inflammatory activity. Formoterol fumarate is a beta-2 adrenergic receptor agonist and acts as a bronchodilator. Dulera is approved in the US where it is indicated for the treatment of asthma in adults and adolescents aged 12 years and above.
Table of Contents
1 Product Profiles- Dulera: Asthma
List of Figures
Figure 1: Dulera for asthma - SWOT analysis
Figure 2: The author’s drug assessment summary of Dulera in asthma
Figure 3: The author’s drug assessment summary of Dulera in asthma
Figure 4: Dulera sales for asthma in the US, 2017-26
List of Tables
Table 1: Dulera drug profile
Table 2: Dulera pivotal trial data in asthma
Table 3: Dulera Phase IV trial in asthma
Table 4: Dulera sales for asthma in the US ($m), 2017-26
Companies Mentioned
- Merck & Co
